Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.
Also called NCT04714177
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 390 participants
- Registry
-
NCT04714177
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04714177. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2023-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage
- Acronym
- ED-ICH
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- Edaravone Dexborneol
- Intervention (Drug)
- Placebo
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Collaborator
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct04714177- Content hash
fa082262bf57efc23d79056342f1b16140a7c598d13b12ca97bcec6b06491798